Evidence map›Paper›PMID 28499022›Full record

Trial reportNeuro-oncology2017

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Patrick Grossmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren Abrey, David A Reardon, Lawrence H Schwartz, Patrick Y Wen, Brian M Alexander, Raymond Huang and 1 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Radiomics in glioma: emerging trends and challenges.Annals of clinical and translational neurology · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Artificial intelligence-based MRI radiomics and radiogenomics in glioma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Patrick GrossmannDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Vivek NarayanDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Ken ChangDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Rifaquat RahmanDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Lauren AbreyDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
David A ReardonDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Lawrence H SchwartzDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Patrick Y WenDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Brian M AlexanderDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Raymond HuangDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.
Hugo J W L AertsDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.

Funding

Neuroimaging Training ProgramT32EB001680 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BRUCE R ROSEN · 2003 to 2026
$3.8M
Quantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5M
Genotype and Imaging Phenotype Biomarkers in Lung CancerU01CA190234 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.3M
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a ModelU01CA140207 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHWARTZ, LAWRENCE H, ZHAO, BINSHENG · 2011 to 2015
$2.8M
Advanced Multimodal Neuroimaging Training GrantR90DA023427 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2006 to 2015
$2.8M
Advanced Multimodal Neuroimaging Training GrantT90DA022759 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2006 to 2015
$1.4M
NCI NIH HHS U01 CA140207NCI NIH HHS U01 CA190234NCI NIH HHS U24 CA194354NIBIB NIH HHS T32 EB001680NIDA NIH HHS R90 DA023427NIDA NIH HHS T90 DA022759
6 · The paper itself

Abstract

backgroundAnti-angiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of MRI have the potential to noninvasively stratify survival and progression in this patient population.

methodsIn an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pretreatment) MRI. These selected features were evaluated on a second cohort of 165 patients from the multicenter BRAIN trial with prospectively acquired clinical and imaging data. Features were evaluated in terms of prognostic value for overall survival (OS), progression-free survival (PFS), and progression within 3, 6, and 9 months using baseline imaging and first follow-up imaging at 6 weeks posttreatment initiation.

resultsMultivariable analysis of features derived at baseline imaging resulted in significant stratification of OS (hazard ratio [HR] = 2.5; log-rank P = 0.001) and PFS (HR = 4.5; log-rank P = 2.1 × 10-5) in validation data. These stratifications were stronger compared with clinical or volumetric covariates (permutation test false discovery rate [FDR] <0.05). Univariable analysis of a prognostic textural heterogeneity feature (information correlation) derived from postcontrast T1-weighted imaging revealed significantly higher scores for patients who progressed within 3 months (Wilcoxon test P = 8.8 × 10-8). Generally, features derived from postcontrast T1-weighted imaging yielded higher prognostic power compared with precontrast enhancing T2-weighted imaging.

conclusionRadiomics provides prognostic value for survival and progression in patients with recurrent glioblastoma receiving bevacizumab treatment. These results could lead to the development of quantitative pretreatment biomarkers to predict benefit from bevacizumab using standard of care imaging.

Indexed as

AdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabBiomarkersBrain NeoplasmsContrast MediaDisease ProgressionFemaleFollow-Up StudiesGlioblastomaHumansImage Processing, Computer-AssistedLymphatic MetastasisMagnetic Resonance ImagingAngiogenesis InhibitorsBevacizumabBiomarkersContrast Mediabevacizumabglioblastomaradiomicsrecurrentsurvival

Identifiers

PMID28499022
PMCPMC5716072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.